11/19/2023 0 Comments Xeljanz copay assistance* Dosage adjustment is needed in patients with moderate and severe renal impairment or moderate hepatic impairment: see full prescribing information. Use the lowest effective dose needed to maintain response. For patients with loss of response during maintenance treatment, XELJANZ 10 mg twice daily or XELJANZ XR 22 mg once daily may be considered and limited to the shortest duration, with careful consideration of the benefits and risks for the individual patient. ![]() * Maintenance: XELJANZ 5 mg twice daily or XELJANZ XR 11 mg once daily. Discontinue XELJANZ 10 mg twice daily or XELJANZ XR 22 mg once daily after 16 weeks if adequate therapeutic response is not achieved. If needed, continue XELJANZ 10 mg twice daily or XELJANZ XR 22 mg once daily for a maximum of 16 weeks. ![]() * Induction: XELJANZ 10 mg twice daily or XELJANZ XR 22 mg once daily for 8 weeks evaluate patients and transition to maintenance therapy depending on therapeutic response. Psoriatic Arthritis (in combination with nonbiologic DMARDs) * Recommended dosage in patients with moderate and severe renal impairment or moderate hepatic impairment is XELJANZ 5 mg once daily. * XELJANZ 5 mg twice daily or XELJANZ XR 11 mg once daily. * Do not initiate XELJANZ/XELJANZ XR/XELJANZ Oral Solution if absolute lymphocyte count <500 cells/mm 3, an absolute neutrophil count (ANC) <1000 cells/mm 3 or hemoglobin <9 g/dL. ![]() * Changes between XELJANZ and XELJANZ XR should be made by the healthcare provider. Administration Instructions * XELJANZ XR (tofacitinib extended-release tablets) is not interchangeable or substitutable with XELJANZ Oral Solution.
0 Comments
Leave a Reply. |
AuthorWrite something about yourself. No need to be fancy, just an overview. ArchivesCategories |